View Entire Prescribing Information OPDIVO® (nivolumab) is indicated with the treatment of Grownup patients with classical Hodgkin lymphoma (cHL) which has relapsed or progressed following autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or following three or more traces of systemic therapy that includes autologo